Dentistry News
-
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
IRVINE, CA / August 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced the appointment of Kevin Belteau as Vice President of Clinical Operations. Mr. Belteau joins enVVeno Medical following a twenty-three-year career in clinical operations at ...
-
enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Ended the quarter with $47.2 million in cash and investments – expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data IRVINE, CA / August 3, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today provided a ...
-
enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein
New Current Procedural Terminology (CPT®) III code establishes a reimbursement pathway for the VenoValve The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading ...
-
Onlume Receives FDA 510(k) Clearance for Fluorescence-guided Surgery Device
OnLume has received 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. This ...
By OnLume Inc.
-
CD Formulation Announces Ability to Develop Liquid Dosage Forms
CD Formulation is known as a CRO service provider for custom pharmaceutical formulation projects. In a recent statement, the company announced its ability in liquid dosage forms development for customers worldwide who are looking for liquid dosage forms solutions for their drug development projects. There are different types of dosage forms, such as solid dosage form, liquid dosage form, ...
-
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged 18 to 64 for the Prevention of Invasive Pneumococcal Disease and Pneumonia Announcement of Topline Safety, Tolerability and Immunogenicity Results from Both the Phase 1 and 2 Portions of the VAX-24 Phase 1/2 Study Expected by the End of 2022 Initiation of ...
-
Vaxcyte to Present at the Jefferies Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 8:30 a.m. ET / 5:30 a.m. PT. A live webcast of the ...
-
Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, today announces that it has signed the definitive subscription agreement for a maximum EUR 5 million convertible bonds (CBs) facility arranged by ABO Securities, through its affiliated entity Global Tech Opportunities 15. The proceeds of the financing will contribute to ...
-
Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has entered into a non-binding term sheet and exclusive discussions for a period of three months with the shareholders of Medsenic, a privately held, clinical stage biopharmaceutical company incorporated in France and specialized in ...
-
Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the Annual General Meeting to be held on Wednesday 8 June 2022 as from 4:00 pm CEST, at Rue Granbonpré 11, Building H, 1435 ...
-
Vaxcyte to Participate in Upcoming Investor Conferences in May
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences: BofA Securities 2022 Healthcare Conference May 10-13, 2022; Las Vegas, NV Fireside chat will ...
-
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update
Ended the quarter with $51.3 million in cash – expected to fund operations through the end of 2024 including release of topline pivotal trial data Ongoing advancement of SAVVE U.S pivotal trial with 20 sites available to enroll patients Progress on development of second device for the treatment of venous disease expected to be unveiled in mid-2022 IRVINE, CA / May 2, 2022 / enVVeno ...
-
enVVeno Medical Announces New U.S. VenoValve Patent
Expanding patent portfolio bolsters protection of the Company’s lead product The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the leg There are currently no effective treatments for patients with deep venous CVI The VenoValve is currently being evaluated in leading hospitals throughout the U.S. in ...
-
Biorez Adds Two Esteemed Surgeons to its Scientific Advisory Board
Biorez Inc., a start-up advancing tendon and ligament healing with its proprietary BioBrace Technology, announced today that the company is expanding its scientific advisory board to include Drs. Joseph Burns of Atlanta and Deryk G. Jones of New Orleans. “Drs. Burns and Jones are both accomplished surgeons, thought leaders, and published researchers in sports medicine, and we are ...
By Biorez Inc.
-
Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ET. A live webcast of the presentation can be ...
-
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia by the End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate ...
-
MatTek Announces Production and Shipping of EpiOral Tissues from European Facility to Better Service the Wider Market
MatTek Life Sciences will produce and distribute EpiOral from its production facility in Slovakia, continuing the BICO groups’ focus on providing on-demand tissues to the European market. MatTek Life Sciences, a Boston-area tissue engineering company and a part of the BICO Group, announced today its European facility in Bratislava, Slovakia, will begin producing and shipping EpiOral, a ...
-
CMR Surgical & Surgical Innovations develop new surgical hybrid port access system
CMR Surgical & Surgical Innovations develop new surgical hybrid port access system Surgical Innovations’ new YelloPort Elite™ 5mm, with reusable trocar and canula, reduces cost and waste generated when compared with traditional fully single use Port Access Systems Developed with CMR Surgical, the port access system is the latest addition to Surgical Innovation’s ...
-
Transparency notification received from Nyenburgh Holding NV
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that it has received a transparency notification dated 16 March 2022 indicating that the shareholdings held by Nyenburgh Holding NV have crossed below the minimum threshold of 5%. The notification dated 16 March 2022 contains the ...
-
Align Technology Receives Top Spots on Institutional Investor’s 2022 All-America Executive Team and Most Honored Company Lists
TEMPE, Ariz., March 09, 2022 (GLOBE NEWSWIRE) -- Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry today announced top-tier recognition for three executives, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you